谷歌抗衰老公司揭秘
|
????至于說這個新公司的管理問題，據說馬里斯一開始就想著要來管理它，同時卻又保持自己在谷歌創投中的位置（有點像杰克?多西所做的那樣）。不過他也廣泛征求各方意見，請求推薦首席執行官的人選。馬里斯求教的人中就有阿特?列文森，他居然真的打算加盟，這真是讓人大跌眼鏡（如果大家沒把他看成是已經從首席管理層崗位上徹底引退的話，他卻也是這個職位的不二人選）。 ????列文森已經開始為新公司物色人選了。在硅谷的一些人看來，這家公司更像是一家要做長期研究的機構，而不是那種幾年里就準備上臨床試驗的生物制藥初創企業。隨著更多人開始準備為Calico公司效力（或是打算這么做），我們也會了解到更多情況。 ????不過現在我們掌握的情況是，這家公司不差錢，比多數大型藥企都更靈活，而且在谷歌最終操盤前，它還吸引了眾多業界知名的投資機構的關注。再者，它的掌門人是一位多數生命科學企業會不惜一切代價都想聘請的高人。所以說，它的開局還真是不賴。（財富中文網） ????譯者：清遠?? |
????As for management, Maris is said to have originally thought about helping to run the new company, while also maintaining his Google Ventures role (kind of a Jack Dorsey sort of thing). But he also reached out to various folks to get names for prospective CEOs. Among those from whom he sought advice was Art Levinson, who surprisingly threw his own hat into the ring (and would have been the obvious choice for this sort of thing, if everyone hadn't viewed him as permanently retired from the C-suite). ????Levinson already has begun interviewing people for positions at Calico, which some in the Valley are viewing as more of a long-term research institute than a biopharma startup that will be in clinical trials within a couple of years. As more people begin to work at Calico (or at least try to), we'll likely learn more about it. ????For now, however, what we know is that the effort is very well-funded with more flexibility than most big pharma, and that it was appealing to a wide swath of respected investors before Google swept in. Plus, it's led by someone who most other life sciences companies would have given their left lab to hire. Not a bad start…? |
最新文章